(Reuters Health)—Patients give the same doctors different ratings depending on where their visit took place, according to a small U.S. study. Although doctors might act differently in an emergency department compared with a calmer office setting, researchers say the results also suggest that ratings are not a completely reliable measure of the quality of care…
Search results for: hospital

From the Expert: Insight into the Intersection of Cancer & Autoimmunity
Research by Dr. Anthony Rosen, MD, and colleagues found a link between cancer and scleroderma, suggesting the immune system may edit cancer cells. In an interview with The Rheumatologist, Dr. Rosen explores the meaning of this finding and its potential…
Patients Get Mixed Reactions from Docs over Mail-Ordered Genetic Tests
(Reuters Health)—Patients who order direct-to-consumer genetic tests report mixed experiences when they take the results to their doctors, a new study found. About a quarter of people who ordered direct-to-consumer genetic testing from such companies as 23andMe reported discussing the results with their primary care doctors. But nearly one in five were not at all…

Tofacitinib Released from FDA REMS Requirement; Plus Biosimilars for Etanercept & Adalimumab Show Promise
Tofacitinib has been released from the FDA’s risk evaluation and mitigation strategy requirement. The FDA is also reviewing a biologics license application for ABP-501, an adalimumab biosimilar. And CHS-0214, a proposed etanercept biosimilar, has met its primary endpoint at Week 24 in an ongoing 52-week study…
Does PTSD Increase Risk of RA for Women?
Multiple studies have linked post-traumatic stress disorder (PTSD) to an increased risk of rheumatoid arthritis (RA), specifically in men. Using data from a 22-year cohort study, researchers were able to analyze the association between PTSD and the risk of RA in women. This large study builds on and expands previous findings by exploring whether the effects of PTSD differ for RA subtypes. As a secondary objective, researchers also examined smoking as a behavioral confounder and/or mediator in the relationship between PTSD and risk for RA…
Hidradenitis Suppurativa Tied to Higher Mortality
NEW YORK (Reuters Health)—Hidradenitis suppurativa (HS) is associated with a significantly increased risk of adverse cardiovascular (CV) outcomes and all-cause mortality, according to Danish researchers. HS is a chronic, inflammatory skin disease and is most common in women. It is typically diagnosed after long delays, Dr. Alexander Egeberg of the University of Copenhagen and colleagues…

Apremilast Proves Effective for PsA with Skin Involvement
A recent Phase 3 clinical trial found apremilast safe and effective for treating patients with active psoriatic arthritis and skin symptoms who found conventional and biologic DMARDs ineffective…
Dermatology & Immunology: Skin Issues Can Present Challenges
SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…
Route of Iron Replacement Doesn’t Impact IBD Activity, Quality of Life
NEW YORK (Reuters Health)—The route of iron replacement therapy alters the gut microbiome and metabolomics in patients with inflammatory bowel disease (IBD), but the route is unrelated to disease activity and quality of life, according to a new study. “Crohn’s disease patients are extremely fragile to disturbances and one might speculate about consequences in long-term…
Pfizer Unit to Pay $784.6 Million in Medicaid Rebate Settlement
(Reuters)—Pfizer Inc. said its Wyeth unit has agreed to pay $784.6 million to settle cases related to the calculation of Medicaid rebates for a gastric drug between 2001 and 2006. The claims alleged that Wyeth’s calculation of rebates for its proton pump inhibitor Protonix (pantoprazole) violated the Federal Civil False Claims Act and other laws…
- « Previous Page
- 1
- …
- 213
- 214
- 215
- 216
- 217
- …
- 319
- Next Page »